Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.

Publication Title

British journal of haematology

Document Type

Article

Publication Date

5-1-2019

Keywords

LYRA; bortezomib; cyclophosphamide; daratumumab; multiple myeloma

Abstract

This United States community study evaluated the combination of daratumumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in newly diagnosed multiple myeloma (NDMM) and relapsed multiple myeloma (RMM). Patients received 4-8 induction cycles of bortezomib 1·5 mg/m

Clinical Institute

Cancer

Specialty

Oncology

Specialty

Hematology

Share

COinS